louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01661218: Complications and Risk Factors Related With Central Venous Catheters in Cancer Patients
Official title: Complications and Risk Factors Related With Central Venous Catheters in Cancer Patients(CVCCP)
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Thrombosis
Infections
Keywords: catheters
Central Venous
complications
cancer
Lead sponsor: Beijing Huanxing Cancer Hospital
Sponsor class: OTHER
First posted: 2012-08-09
Enrollment: 3500
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All adult cancer patients with CVC and PICC placed at BeijingHCH and with written consent for this study

Brief summary: The investigators aim to determine the complications and risk factors related with peripherally inserted central catheters (PICCs) and central venous catheters (CVCs) in cancer patients.

Detailed description: The purpose of this study is to determine the complications and risk factors related with peripherally inserted central catheters (PICCs) and central venous catheters (CVCs) in cancer patients.

Eligibility criteria: Inclusion Criteria:

* all adult cancer patients with central venous catheters (CVCs) or peripherally inserted central catheters (PICCs) placed at BeijingHCH.

Exclusion Criteria:

* without written informed consent

Primary outcomes:
measure: Catheter-related venous thrombosis and catheter-related infections
timeFrame: 30 days after PICC and CVC line withdrawn
Secondary outcomes:
measure: Catheter tip position
timeFrame: participants will be followed before PICC and CVC line withdrawn
Other outcomes:
Locations:
city: Beijing
country: China
facility: Beijing Huanxing Cancer Hospital
state: Beijing
Study officials:
affiliation: Beijing Huanxing Cancer Hospital
name: Jian DING, MD
role: STUDY_CHAIR
References:
Clinical trial NCT02198118: Domiciliary Physiotherapy During Breast Cancer Radiation
Official title: Domiciliary Physiotherapy During Breast Cancer Radiation
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Shoulder Pain
Keywords: breast cancer
physiotherapy
radiotherapy
Lead sponsor: University of Sao Paulo
Sponsor class: OTHER
First posted: 2014-07-23
Enrollment: 36
Sex: FEMALE
Minimum age (years): 30
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: Background: Breast cancer is the most common type of cancer among women. Its treatment, including radiotherapy (RT), can cause potential complications to be treated by the physiotherapy. Objective: To evaluate the effect of domiciliary physiotherapy on the upper limb applied during the period of radiotherapy in women submitted to surgical and radiotherapy for breast cancer. Study design: This is a prospective randomized controlled clinical trial. Methods: Thirty six volunteers were recruited from November 2009 to March 2012 and they were appraised at three different times: pre-RT, post-RT and 2 months after the end of RT. The parameters evaluated were: shoulder range of movement (ROM) and arm circumference. They were divided into two groups: CG) control group, submitted only to the assessments and SG) study group, submitted to domiciliary physiotherapy.


Eligibility criteria: Inclusion Criteria:

- Having been diagnosed with unilateral breast cancer and having been submitted to surgical and radiation treatment as part of the treatment for breast cancer, according to the therapeutic protocol of the unit

Exclusion Criteria:

- Patients with neurological or orthopedic diseases that could impair the movements of the upper limbs, bilateral breast cancer, previous thoracic radiotherapy, and the presence of distant metastasis.

Primary outcomes:
measure: Gain in range of movement measured in degrees
timeFrame: Three months
Secondary outcomes:
measure: Improvement of lymphedema measured in centimeters
timeFrame: Three months
Other outcomes:
Locations:
city: Ribeirão Preto
country: Brazil
facility: Hospital das Clínicas de Ribeirão Preto
state: SP
Study officials:
affiliation: University of Sao Paulo
name: Nara FB Leal, Master
role: STUDY_CHAIR
References:
citation: Leal NF, Oliveira HF, Carrara HH. Supervised physical therapy in women treated with radiotherapy for breast cancer. Rev Lat Am Enfermagem. 2016 Aug 15;24:e2755. doi: 10.1590/1518-8345.0702.2755.
Clinical trial NCT04781218: ABC Science Collaborative Registry Study
Official title: ABC Science Collaborative Registry Study
Study type: OBSERVATIONAL
Overall status: WITHDRAWN
Conditions: COVID19
Lead sponsor: Duke University
Sponsor class: OTHER
First posted: 2021-03-04
Enrollment: 0
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: School community members, including students, parents, staff, etc.

Brief summary: The ABC Registry is associated with Pro00107943 and provides a resource for collecting information on members of school communities both regionally in North and South Carolina, as well as nationally in the United States (U.S.) through the National Program, including children, parents, teachers, superintendents, and other staff; and children identified through clinical practice. The overall goals of the Registry are to collect data relevant to public health during the coronavirus 2019 (COVID-19) pandemic and to establish and engage school communities that may be eligible for participation in future research studies, including observational studies, as well as prospective COVID-19 trials.


Eligibility criteria: Inclusion Criteria:

* Participant currently attends, is the parent of a student, works in, or works with a school that is participating in the ABC Science Collaborative, or participant is an adult or child who learned of the registry through clinical practice and is interested in participating in COVID-19 related research,
* Participant or their parent/guardian has provided informed consent or assent, as applicable
* Participant or their parent/guardian has downloaded the "ABC Science" App from the App store as a part of the ABC Science Collaborative and has agreed to the App's Terms of Use
* Participant or their parent/guardian is able to speak and read English or Spanish

Exclusion Criteria:

* There are no specific exclusion criteria for this registry. Participants must meet inclusion criteria.

Primary outcomes:
measure: Participants who enroll in the ABC Registry
timeFrame: Up to 5 years
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Duke University
name: Kanecia Zimmerman, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01185418: Evaluation of Negative Symptoms and Cognitive Function After Administration of Antipsychotics in Healthy Volunteer
Official title: Evaluation of Negative Symptoms and Cognitive Function After Administration of Antipsychotics in Healthy Volunteer: a Double-blind, Randomized Trial of a Single Dose of Placebo, Haloperidol, Amisulpride, Risperidone and Aripiprazole
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Normal Volunteers
Lead sponsor: Chonbuk National University Hospital
Sponsor class: OTHER
First posted: 2010-08-20
Enrollment: 80
Sex: ALL
Minimum age (years): 18
Maximum age (years): 38
Standard ages: ADULT
Accepts healthy volunteers: yes
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Recruited volunteers among normal adults aged from 18 to 38 who responded advertisements for research subjects. Then selected subjects from the applicants using various screening tests - physical and neurological examination including confirming vital signs after examining physical health and sleep habits of volunteers

Brief summary: The aim of the study is to investigate the negative symptoms and cognitive function after administration of antipsychotics in healthy volunteer.


Eligibility criteria: Inclusion Criteria:

* Aged 18-38 years and meet no DSM-IV diagnostic criteria as assessed by using the Structured Clinical Interview for DSM-IV, research version.

Exclusion Criteria:

* 1) anyone who participated in other clinical trials within 30 days from the start of this clinical trial or is currently participating in one,
* 2) anyone who has progressive disease or in unstable medical condition unfit for the trial,
* 3) anyone who has been diagnosed in psychiatric terms in the past, depends on psychotropic substance, or has overdosed or depended on the substance or alcohol (except for coffee or tobacco) within 1 month from the trial start,
* 4) anyone who is suicidal or highly probable of suicides, or
* 5) anyone who has test results considered clinically meaningful

Primary outcomes:
measure: Symptoms assessment by objective and subjective rating scale
timeFrame: 2 hour
measure: Symptoms assessment by objective and subjective rating scales & CNT
timeFrame: 4hour
measure: Symptoms assessment by objective and subjective rating scales
timeFrame: 24hour
Secondary outcomes:
measure: Symptoms assessment by objective rating scale
timeFrame: 4hour
measure: Symptoms assessment by objective rating scale
timeFrame: 24hour
Other outcomes:
Locations:
city: Jeonju
country: Korea, Republic of
facility: Chonbuk national university hospital
Study officials:
References:
Clinical trial NCT01700218: Integrated Telemonitoring and Nurse Support Evaluation
Official title: Integrated Telemonitoring and Nurse Support Evaluation in Heart Failure
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Chronic Heart Failure
Keywords: telemonitoring
Lead sponsor: Medical University of Graz
Sponsor class: OTHER
Collaborators: name: Ludwig Boltzmann Institute for translational heart failure research
name: AIT Austrian Institute of Technology GmbH
First posted: 2012-10-04
Enrollment: 350
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of the study is to test a new medical device for optimizing treatment of heart failure and compare its effect on outcome of patients with a recent hospitalization for worsening heart failure

Detailed description: Patients after an episode of acute heart failure have an increased risk of rehospitalisation and impaired prognosis for survival. Neither a sole mobile nurse support nor a sole telemonitoring system has been able to provide consistent data on a beneficial influence on prognosis. Furthermore, the influence of frequent measurements of NT-pro-BNP in a home setting of heart failure patients has not been investigated so far.

This study will test a new medical device (software) for optimizing treatment of heart failure patients and evaluate its impact on outcome of these patients.

Eligibility criteria: Inclusion Criteria:

* acute systolic heart failure with admission for at least 4 consecutive days
* treatment with an ACE-inhibitor/angiotensin receptor blocker, beta-blocker, mineralocorticoid receptor antagonist according to current ESC-guidelines
* treatment with a loop diuretic
* stable renal function (eGFR according to MDRD of at least 30ml)
* written informed consent
* minimum age of 18 years

Exclusion Criteria:

* unstable coronary artery disease with revascularisation of any type within the last two months
* planned revascularisation or operation for valvular heart disease within the next 6 months
* planned heart transplantation
* uncontrolled hypertension
* active myocarditis
* malignant disease with a life expectancy of less than 18 months
* chronic use of high-dose NSAID or COX-2-inhibitors
* psychiatric disorders that make it unlikely to understand the protocol
* participation in an other randomized trial
* inability to operate a smartphone

Primary outcomes:
measure: all cause mortality and hospitalization for worsening heart failure
timeFrame: 12 months
Secondary outcomes:
measure: days alive and out of hospital
timeFrame: 12 months
Other outcomes:
measure: exploratory endpoint
timeFrame: 12 months
Locations:
city: Graz
country: Austria
facility: Medical University
Study officials:
affiliation: Medical University of Graz
name: Friedrich M Fruhwald, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04699318: Urethrocutaneous Fistula Rate After Double Dartos and Single Dartos Tubularized Incised Plate Urethroplasty
Official title: To Compare the Frequency of Urethrocutaneous Fistula After Double Dartos Tubularized Incised Plate (TIP) Urethroplasty and Single Dartos Tubularized Incised
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Hypospadias
Lead sponsor: King Edward Medical University
Sponsor class: OTHER
First posted: 2021-01-07
Enrollment: 60
Sex: MALE
Minimum age (years): 2
Maximum age (years): 17
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The subjects were divided into two groups. Each group comprised 30 children. Children were randomly allocated in two groups via computer generated tables. Children in group-A underwent single dartos tubularized incised plate urethroplasty while those in group-B underwent double dartos tubularized incised plate urethroplasty.

Detailed description: In group A dartos flap is raised from foreskin of the patient and applied as a single layer after tubularization in between neourethra and skin . In group B dartos flap is raised from the foreskin of patient and divided in two equal halves.Both flaps are placed as two layers in between skin and neourethra.After surgery patient is kept in ward for 10 days with stent.Patient is followed up in OPD on after 7th day after discharge for outcome.

Eligibility criteria: Inclusion Criteria All the patients above one year of age All patients having distal and mid penile hypospadias. -

Exclusion Criteria Severe chordee Previously operated cases Patient with undescended testis Circumcised patient

-

Primary outcomes:
measure: Recurrence of urethro-cutaneous fistula
timeFrame: 17 days
Secondary outcomes:
Other outcomes:
Locations:
city: Lahore
country: Pakistan
facility: KEMU
state: Punjab
Study officials:
affiliation: King Edward Medical University
name: Asad Munir, FCPS
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00634218: Reaching and Treating Lesbian, Gay, Bisexual, and Transgender (LGBT) Cigarette Smokers
Official title: REaching and Treating LGBT Smokers: The Internet
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
PHASE3
Conditions: Cigarette Smoking
Keywords: nicotine
smoking
smoking cessation
Lead sponsor: University of California, San Francisco
Sponsor class: OTHER
Collaborators: name: Tobacco Related Disease Research Program
First posted: 2008-03-12
Enrollment: 363
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: FACTORIAL
Primary purpose: TREATMENT

Brief summary: Smoking rates are significantly higher among lesbian, gay, bisexual, and transgender (LGBT) populations compared to the general population. LGBT individuals may be at increased risk for experiencing psychosocial issues, e.g., negative moods, stress, alcohol/drug use, that have been associated with smoking treatment failure in other groups of smokers. Technology, such as the Internet and telephone, can be an effective method to reach a large number of smokers and may be particularly effective in reaching hidden populations. Thus, the study seeks to examine whether Internet-based counseling and/or telephone counseling can improve quit rates for LGBT smokers.

Participants (N=600) will be randomly assigned to one of four conditions: 1) a Mail-based Self Help (MSH) treatment; 2) MSH plus an Internet-based Smoking Treatment (IST); MSH plus Telephone Counseling (TC) or 4) MSH plus IST plus TC. Participants in the MSH condition will receive a self-help smoking cessation manual. In the IST condition, participants will receive the manual plus access to an Internet-based intervention that includes social support. In the TC condition, participants will receive the manual plus 6 telephone-based counseling sessions. In the fourth condition, participants will receive the manual plus access to an Internet-based intervention plus telephone counseling. Before starting treatment, participants will complete questionnaires on smoking, nicotine dependence, demographics, negative mood, and alcohol use. Participants will be contacted at 3, 6, and 12 months after enrollment to determine whether they are smoking. The data will be analyzed to compare the efficacy of the four treatments and to examine the possible influence of existing social networks and level of negative mood on treatment outcome and to examine the possible influence of residency (rural versus urban) on use of the Internet-based treatment.


Eligibility criteria: Inclusion Criteria:

* 18 years of age
* identify as lesbian, gay, bisexual, or transgender
* access to the internet
* valid email account
* valid telephone number
* English speaking
* resident of the U.S.

Exclusion Criteria:

-

Primary outcomes:
measure: Smoking status
timeFrame: 3,6, and 12 months following enrollment.
Secondary outcomes:
Other outcomes:
Locations:
city: San Francisco
country: United States
facility: Univeristy of California, San Francisco
state: California
Study officials:
References:
Clinical trial NCT06537518: The Difference Between Using Local and General Dexamethasone in Arthroscopic Anterior Cruciate Ligament Repair
Official title: Adductor Canal Block With Dexamethasone Versus Adductor Canal Block With Systemic Dexamethasone in Arthroscopic Anterior Cruciate Ligament Repair
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: ACL Injury
Lead sponsor: Benha University
Sponsor class: OTHER
First posted: 2024-08-05
Enrollment: 123
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Arthroscopic knee injuries, such as the anterior cruciate ligament (ACL) injury, are common and often result in postoperative pain. Regional anesthetic techniques, such as femoral nerve block (FNB) and adductor canal block (ACB), can help alleviate pain and reduce opioid consumption. ACB, which blocks the saphenous nerve and obturator nerve branches, is preferred over FNB due to its potential to decrease mobility and increase falls risk. Dexamethasone, a potent glucocorticoid, is used as an adjuvant for ACB, but its perineural administration may carry neurotoxicity risks. Some pain physicians prefer intravenous administration to prolong the action of local anesthetics used in peripheral nerve blocks.


Eligibility criteria: Inclusion Criteria:

* Patients diagnosed with ACL injury;
* Patients in class I, II according to American Society of Anesthesiologists (ASA) classification.

Exclusion Criteria:

* Patients free of all Inclusion Criteria.

Primary outcomes:
measure: Proportion of patients reporting at least a 50% reduction in pain (measured by Numerical Rating Scale) post-arthroscopic ACL management.
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Banhā
country: Egypt
facility: Benha faculty of Medicine
state: El Qalyoubia
Study officials:
References:
Clinical trial NCT00298818: Open Label Study of Zonisamide in the Treatment of Epilepsy in Patients With Mental Retardation
Official title: Open Label Study of Zonisamide in the Treatment of Epilepsy in Patients With Mental Retardation / Developmental Disabilities
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Epilepsy
Mental Retardation
Developmental Disabilities
Keywords: Epilepsy
Mental Retardation
Developmental Disabilities
Lead sponsor: Northwell Health
Sponsor class: OTHER
Collaborators: name: Eisai Inc.
First posted: 2006-03-03
Enrollment: 25
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Epilepsy center

Brief summary: The purpose of this study is to assess the efficacy and tolerability in "real-world" clinical practice, of adjunctive zonisamide treatment in adult patients with developmental disabilities and epilepsy.

Detailed description: While a number of randomized double-blind controlled trials have demonstrated the value of zonisamide in the treatment of seizures, such studies lend limited insight into the efficacy and tolerance of zonisamide in real-world clinical practice. Furthermore, randomized trials tend to inquire about negative effects, such as adverse reactions, while positive effects such as improvement in mood, or sense of well-being are not similarly categorized. In addition, there is little information about experience with zonisamide specifically in adult patients with mental retardation (MR) / developmental disabilities (DD). Anecdotal experience suggests that zonisamide is exceptionally well-tolerated, and is associated with an improved general sense of well-being and quality of life in non-DD patients. In patients with MR/DD, observational studies that promote awareness of such distinguishing features and other aspects of efficacy are essential for guiding decision-making when prescribing antiepileptic drugs.

Eligibility criteria: Inclusion Criteria:

* Male or Female, at least 18 years of age
* Diagnosis of mental retardation
* Uncontrolled seizures or intolerable side effects from current AEDs
* Legal guardian is able to consent

Exclusion Criteria:

* Sulfa allergy
* Prior exposure to zonisamide

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: New Hyde Park
country: United States
facility: Long Island Jewish Medical Center
state: New York
Study officials:
affiliation: Northwell Health
name: Alan Ettinger, MD
role: PRINCIPAL_INVESTIGATOR
References: